# A Study of Comparing Talquetamab to Belantamab Mafodotin in Participants With Relapsed/Refractory Multiple Myeloma

> **NCT05461209** · PHASE3 · WITHDRAWN · sponsor: **Janssen Research & Development, LLC**

## Conditions studied

- Relapsed/ Refractory Multiple Myeloma

## Interventions

- **DRUG:** Talquetamab
- **DRUG:** Belantamab Mafodotin

## Key facts

- **NCT ID:** NCT05461209
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-10-20
- **Primary completion:** 2022-11-15
- **Final completion:** 2024-10-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Business Decision
- **Last updated:** 2025-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05461209

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05461209, "A Study of Comparing Talquetamab to Belantamab Mafodotin in Participants With Relapsed/Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05461209. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*